Our unique approach is achieved by rearranging the DNA sequences of two monoclonal antibodies into three genetic constructs, and co-expressing them in mammalian cells. This technology platform does not require added complexities of Fc mutations, scFv elements, linkers nor peptide connectors to generate bispecific antibodies. The Fab domains in each arm work “in tandem” to form a tetravalent bispecific antibody with four active and independent antigen binding sites that fully retain the biological function of their parental antibodies. Having already advanced several FIT-Ig® molecules into the clinic, EpimAb has accumulated extensive technical know-how and scientific insights to further expand the unique features and overall capabilities of this new drug format.